PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
122.89
Positive P/E while Drug Manufacturers - Specialty & Generic median is negative at -1.01. Peter Lynch would investigate competitive advantages in a distressed Drug Manufacturers - Specialty & Generic.
19.47
P/S 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 13.27. Guy Spier would scrutinize if premium reflects durable advantages.
1.52
P/B 50-90% of Drug Manufacturers - Specialty & Generic median of 1.72. Mohnish Pabrai would examine if this discount presents opportunity.
-30.99
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -8.36. Seth Klarman would investigate cash flow improvement potential.
-53.28
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
1.52
Fair value ratio 50-90% of Drug Manufacturers - Specialty & Generic median of 1.71. Mohnish Pabrai would examine if this gap presents opportunity.
0.20%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-3.23%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.18%. Seth Klarman would investigate cash flow improvement potential.